Considering the extensive crosstalk among the three pathways, the combined inhibition of the EGFR, cMET, and VEGF pathways could overcome resistance and could be an effective treatment approach for NSCLC patients. The gene discussed is MET; the disease is non-small cell lung carcinoma.